Gately Bio

Gately Bio is a preclinical-stage biotechnology company focused on developing next-generation biologics that can cross the blood-brain barrier (BBB) to treat central nervous system (CNS) manifestations of rare genetic diseases. The company's primary focus is on lysosomal storage disorders (LSDs), where current enzyme replacement therapies often fail to address neurological symptoms due to their inability to reach the brain. Gately Bio utilizes a proprietary protein engineering platform to create CNS-penetrant enzymes, aiming to provide comprehensive treatment for both systemic and neurological aspects of these conditions. Led by a team of experienced executives from Audentes Therapeutics, the company is backed by top-tier investors including ARCH Venture Partners and F-Prime Capital. Gately Bio is headquartered in South San Francisco, California.